Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease

Jane L Benjamin; Charlotte R H Hedin; Andreas Koutsoumpas; Siew C Ng; Neil E McCarthy; Ailsa L Hart; Michael A Kamm; Jeremy D Sanderson; Stella C Knight; Alastair Forbes; Andrew J Stagg; Kevin Whelan; James O Lindsay

doi:10.1136/gut.2010.232025

Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease

Jane L Benjamin, Charlotte R H Hedin, Andreas Koutsoumpas, Siew C Ng, Neil E McCarthy, Ailsa L Hart, Michael A Kamm, Jeremy D Sanderson, Stella C Knight, Alastair Forbes, Andrew J Stagg, Kevin Whelan, James O Lindsay

Research output: Contribution to journal › Article › peer-review

279 Citations (Scopus)

Abstract

The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.

Original language	English
Pages (from-to)	923-9
Number of pages	7
Journal	Gut
Volume	60
Issue number	7
DOIs	https://doi.org/10.1136/gut.2010.232025
Publication status	Published - Jul 2011

Keywords

Adult
Bifidobacterium
Crohn Disease
Dendritic Cells
Double-Blind Method
Feces
Female
Humans
Immunity, Mucosal
Intestinal Mucosa
Male
Medication Adherence
Middle Aged
Oligosaccharides
Prebiotics
Rectum
Treatment Outcome

Access to Document

10.1136/gut.2010.232025

Cite this

Benjamin, Jane L ; Hedin, Charlotte R H ; Koutsoumpas, Andreas ; Ng, Siew C ; McCarthy, Neil E ; Hart, Ailsa L ; Kamm, Michael A ; Sanderson, Jeremy D ; Knight, Stella C ; Forbes, Alastair ; Stagg, Andrew J ; Whelan, Kevin ; Lindsay, James O. / Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. In: Gut. 2011 ; Vol. 60, No. 7. pp. 923-9.

@article{1ccedddf9658408eb0c52c8432e99bbb,

title = "Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease",

abstract = "The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.",

keywords = "Adult, Bifidobacterium, Crohn Disease, Dendritic Cells, Double-Blind Method, Feces, Female, Humans, Immunity, Mucosal, Intestinal Mucosa, Male, Medication Adherence, Middle Aged, Oligosaccharides, Prebiotics, Rectum, Treatment Outcome",

author = "Benjamin, {Jane L} and Hedin, {Charlotte R H} and Andreas Koutsoumpas and Ng, {Siew C} and McCarthy, {Neil E} and Hart, {Ailsa L} and Kamm, {Michael A} and Sanderson, {Jeremy D} and Knight, {Stella C} and Alastair Forbes and Stagg, {Andrew J} and Kevin Whelan and Lindsay, {James O}",

year = "2011",

month = jul,

doi = "10.1136/gut.2010.232025",

language = "English",

volume = "60",

pages = "923--9",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "7",

}

Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. / Benjamin, Jane L; Hedin, Charlotte R H; Koutsoumpas, Andreas; Ng, Siew C; McCarthy, Neil E; Hart, Ailsa L; Kamm, Michael A; Sanderson, Jeremy D; Knight, Stella C; Forbes, Alastair; Stagg, Andrew J; Whelan, Kevin; Lindsay, James O.

In: Gut, Vol. 60, No. 7, 07.2011, p. 923-9.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease

AU - Benjamin, Jane L

AU - Hedin, Charlotte R H

AU - Koutsoumpas, Andreas

AU - Ng, Siew C

AU - McCarthy, Neil E

AU - Hart, Ailsa L

AU - Kamm, Michael A

AU - Sanderson, Jeremy D

AU - Knight, Stella C

AU - Forbes, Alastair

AU - Stagg, Andrew J

AU - Whelan, Kevin

AU - Lindsay, James O

PY - 2011/7

Y1 - 2011/7

N2 - The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.

AB - The commensal intestinal microbiota drive the inflammation associated with Crohn's disease. However, bacteria such as bifidobacteria and Faecalibacterium prausnitzii appear to be immunoregulatory. In healthy subjects the intestinal microbiota are influenced by prebiotic carbohydrates such as fructo-oligosaccharides (FOS). Preliminary data suggest that FOS increase faecal bifidobacteria, induce immunoregulatory dendritic cell (DC) responses and reduce disease activity in patients with Crohn's disease.

KW - Adult

KW - Bifidobacterium

KW - Crohn Disease

KW - Dendritic Cells

KW - Double-Blind Method

KW - Feces

KW - Female

KW - Humans

KW - Immunity, Mucosal

KW - Intestinal Mucosa

KW - Male

KW - Medication Adherence

KW - Middle Aged

KW - Oligosaccharides

KW - Prebiotics

KW - Rectum

KW - Treatment Outcome

U2 - 10.1136/gut.2010.232025

DO - 10.1136/gut.2010.232025

M3 - Article

C2 - 21262918

VL - 60

SP - 923

EP - 929

JO - Gut

JF - Gut

SN - 0017-5749

IS - 7

ER -